US 2009/0156528 A1 · RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS C VIRUS (HCV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)

Abstract

The present invention concerns methods and reagents useful in modulating hepatitis C virus (HCV) gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against hepatitis C virus (HCV) gene expression and/or activity. The small nucleic acid molecules are useful in the treatment and diagnosis of HCV infection, liver failure, hepatocellular carcinoma, cirrhosis and any other disease or condition that responds to modulation of HCV expression or activity.

Claims20

Dependent claims

A chemically modified nucleic acid molecule, wherein:

(a) the nucleic acid molecule comprises a sense strand and a separate antisense strand, each strand having one or more pyrimidine nucleotides and one or more purine nucleotides;
(b) each strand of the nucleic acid molecule is independently 18 to 27 nucleotides in length;
(c) an 18 to 27 nucleotide sequence of the antisense strand is complementary to a human HCV RNA sequence comprising SEQ ID NO:
1706;
(d) an 18 to 27 nucleotide sequence of the sense strand is complementary to the antisense strand and comprises an 18 to 27 nucleotide sequence of the human RNA sequence;
and
(e) 50 percent or more of the nucleotides in each strand comprise a 2′-sugar modification, wherein the 2′-sugar modification of any of the pyrimidine nucleotides differs from the 2′-sugar modification of any of the purine nucleotides.

4 more elements

Dependencies are inferred from the claim text.

Facts

Application

12/137,411Filed 11 Jun 2008

Priority

20 Feb 2002

Published

18 Jun 2009

Term ends

Not estimatedThe source records don’t support an estimate.

Classification37 codes

C12N 15/1132
Against viruses: against retroviridae, e.g. HIV
A61K 47/54
The non-active ingredient being a modifying agent: the modifying agent being an organic compound
A61P 1/16
Drugs for disorders of the alimentary tract or the digestive system: for liver or gallbladder disorders, e.g. hepatoprotective agents,…
A61P 31/14
Antivirals: for RNA viruses

Family

Application60/358,580Us provisional application · filed 20 Feb 2002

Application60/363,124Us provisional application · filed 11 Mar 2002

Application60/386,782Us provisional application · filed 6 Jun 2002

Application60/401,104Us provisional application · filed 5 Aug 2002

Application60/406,784Us provisional application · filed 29 Aug 2002

Application60/408,378Us provisional application · filed 5 Sep 2002

Application60/409,293Us provisional application · filed 9 Sep 2002

Application60/440,129Us provisional application · filed 15 Jan 2003

Application10/444,853Continuation in part · filed 23 May 2003

Application10/667,271Continuation · filed 16 Sep 2003

Application12/137,411Continuation

Application10/667,271Continuation in part

US 2004/0192626 A1Published application

US 2004/0209831 A1Published application

US 7,915,400 B2Related patent

US 8,202,979 B2Related patent

US 2009/0156528 A1This patent

From the US filing history. Foreign family members aren’t listed.

RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS C VIRUS (HCV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)

Life of this patent

RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS C VIRUS (HCV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)

Life of this patent

Abstract

Claims20